By Colin Kellaher
Novan Inc. on Friday said it has filed with the U.S. Food and Drug Administration seeking marketing approval of its berdazimer gel 10.3% product for the topical treatment of the skin disease molluscum contagiosum.
The Durham, N.C., medical-dermatology company said it anticipates a potential FDA green light in the first quarter of 2024, assuming the agency accepts the filing under its typical 12-month review process.
Novan said berdazimer gel has the potential to be the first FDA-approved prescription product for the treatment of molluscum contagiosum, a common viral skin infection that causes round, firm bumps.
Shares of Novan, which closed Thursday at $2.04, were recently up 3.4% in premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
01-06-23 0833ET